Price T Rowe Associates Inc Ultragenyx Pharmaceutical Inc. Transaction History

Price T Rowe Associates Inc

  • $869 Billion
  • Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,068,654 shares of RARE stock, worth $139 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,068,654
Previous 2,991,958 2.56%
Holding current value
$139 Million
Previous $123 Million 38.62%
% of portfolio
0.02%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$40.21 - $59.36 $3.08 Million - $4.55 Million
76,696 Added 2.56%
3,068,654 $170 Million
Q2 2024

Aug 14, 2024
SELL
$37.42 - $51.61 $21.6 Million - $29.8 Million
-576,915 Reduced 16.17%
2,991,958 $123 Million
Q1 2024

May 15, 2024
BUY
$43.02 - $53.69 $5.17 Million - $6.45 Million
120,175 Added 3.48%
3,568,873 $167 Million
Q4 2023

Feb 14, 2024
BUY
$31.73 - $49.19 $9.16 Million - $14.2 Million
288,538 Added 9.13%
3,448,698 $165 Million
Q3 2023

Nov 14, 2023
SELL
$34.92 - $46.66 $15.9 Million - $21.2 Million
-454,832 Reduced 12.58%
3,160,160 $113 Million
Q2 2023

Aug 14, 2023
BUY
$37.35 - $52.15 $2.66 Million - $3.71 Million
71,231 Added 2.01%
3,614,992 $167 Million
Q1 2023

May 15, 2023
SELL
$36.99 - $48.71 $20.4 Million - $26.9 Million
-552,627 Reduced 13.49%
3,543,761 $142 Million
Q4 2022

Feb 14, 2023
SELL
$33.72 - $46.33 $22.3 Million - $30.6 Million
-660,568 Reduced 13.89%
4,096,388 $190 Million
Q3 2022

Nov 14, 2022
SELL
$39.96 - $66.14 $241 Million - $398 Million
-6,023,200 Reduced 55.87%
4,756,956 $197 Million
Q2 2022

Aug 15, 2022
SELL
$45.8 - $85.4 $50.6 Million - $94.3 Million
-1,104,630 Reduced 9.29%
10,780,156 $643 Million
Q1 2022

May 16, 2022
BUY
$62.2 - $84.4 $22.4 Million - $30.4 Million
359,697 Added 3.12%
11,884,786 $863 Million
Q4 2021

Feb 14, 2022
BUY
$73.71 - $87.86 $4.87 Million - $5.8 Million
66,043 Added 0.58%
11,525,089 $969 Million
Q3 2021

Nov 15, 2021
BUY
$77.92 - $102.4 $35.8 Million - $47.1 Million
459,832 Added 4.18%
11,459,046 $1.03 Billion
Q2 2021

Aug 16, 2021
BUY
$92.19 - $115.71 $30.2 Million - $37.9 Million
327,428 Added 3.07%
10,999,214 $1.05 Billion
Q1 2021

May 17, 2021
BUY
$106.9 - $167.73 $128 Million - $201 Million
1,201,294 Added 12.68%
10,671,786 $1.22 Billion
Q4 2020

Feb 16, 2021
BUY
$84.4 - $177.39 $799 Million - $1.68 Billion
9,470,492 New
9,470,492 $1.31 Billion

Others Institutions Holding RARE

# of Institutions
326
Shares Held
85.7M
Call Options Held
520K
Put Options Held
406K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.18B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email